150 related articles for article (PubMed ID: 29128554)
1. Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study.
Marinelli Busilacchi E; Costantini A; Viola N; Costantini B; Olivieri J; Butini L; Mancini G; Scortechini I; Chiarucci M; Poiani M; Poloni A; Leoni P; Olivieri A
Biol Blood Marrow Transplant; 2018 Feb; 24(2):267-275. PubMed ID: 29128554
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic immune monitoring of CD4
Lu Z; Xu N; Zhou X; Gao G; Li L; Huang J; Li Y; Lu Q; He B; Pan C; Liu X
Oncol Lett; 2017 Aug; 14(2):1363-1372. PubMed ID: 28808483
[TBL] [Abstract][Full Text] [Related]
3. Foxp3(high) and Foxp3(low) Treg cells differentially correlate with T helper 1 and natural killer cells in peripheral blood.
Lee SK; Kim JY; Jang BW; Hur SE; Na BJ; Lee M; Fukui A; Gilman-Sachs A; Kwak-Kim J
Hum Immunol; 2011 Aug; 72(8):621-6. PubMed ID: 21600259
[TBL] [Abstract][Full Text] [Related]
4. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
El Missiry M; Adnan Awad S; Rajala HL; Al-Samadi A; Ekblom M; Markevän B; Åstrand-Grundström I; Wold M; Svedahl ER; Juhl BR; Bjerrum OW; Haulin I; Porkka K; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S
J Cancer Res Clin Oncol; 2016 May; 142(5):1041-50. PubMed ID: 26746653
[TBL] [Abstract][Full Text] [Related]
5. [Effects of Tyrosine Kinase Inhibitors on the Th1 and Treg Cells of CML Patients].
Dai JY; Yang X; Wei Q; Li H; Huang XB; Wang XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):25-32. PubMed ID: 30738443
[TBL] [Abstract][Full Text] [Related]
6. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
7. Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.
Akashi N; Matsumoto I; Tanaka Y; Inoue A; Yamamoto K; Umeda N; Tanaka Y; Hayashi T; Goto D; Ito S; Sekiguchi K; Sumida T
Mod Rheumatol; 2011 Jun; 21(3):267-75. PubMed ID: 21188449
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
[TBL] [Abstract][Full Text] [Related]
9. Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro.
Nerreter T; Distler E; Köchel C; Einsele H; Herr W; Seggewiss-Bernhardt R
Exp Hematol; 2013 Jul; 41(7):604-614.e4. PubMed ID: 23466625
[TBL] [Abstract][Full Text] [Related]
10. Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127(low) regulatory T cells.
Walter GJ; Evans HG; Menon B; Gullick NJ; Kirkham BW; Cope AP; Geissmann F; Taams LS
Arthritis Rheum; 2013 Mar; 65(3):627-38. PubMed ID: 23280063
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.
Polimeno M; Napolitano M; Costantini S; Portella L; Esposito A; Capone F; Guerriero E; Trotta A; Zanotta S; Pucci L; Longo N; Perdonà S; Pignata S; Castello G; Scala S
BJU Int; 2013 Sep; 112(5):686-96. PubMed ID: 23495770
[TBL] [Abstract][Full Text] [Related]
12. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M
Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
14. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
[TBL] [Abstract][Full Text] [Related]
15. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
16. Shaping of CD56
Ni M; Wang L; Yang M; Neuber B; Sellner L; Hückelhoven-Krauss A; Schubert ML; Luft T; Hegenbart U; Schönland S; Wuchter P; Chen BA; Eckstein V; Krüger W; Yerushalmi R; Beider K; Nagler A; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
Front Immunol; 2019; 10():547. PubMed ID: 30949182
[TBL] [Abstract][Full Text] [Related]
17. Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia.
Varda-Bloom N; Danylesko I; Shouval R; Eldror S; Lev A; Davidson J; Rosenthal E; Volchek Y; Shem-Tov N; Yerushalmi R; Shimoni A; Somech R; Nagler A
Oncotarget; 2017 Jan; 8(1):418-429. PubMed ID: 27880933
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid hormone differentially modulates the in vitro expansion and cytokine profile of thymic and splenic Treg cells.
Pap R; Ugor E; Litvai T; Prenek L; Najbauer J; Németh P; Berki T
Immunobiology; 2019 Mar; 224(2):285-295. PubMed ID: 30612787
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model.
Geisler K; Reischer A; Kroeger I; Jacobs B; Meinhardt K; Bauer R; Ryffel B; Mackensen A; Ullrich E
Oncol Rep; 2014 May; 31(5):2015-20. PubMed ID: 24626639
[TBL] [Abstract][Full Text] [Related]
20. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]